Lista de obras -

A Phase 3 Trial of Bevacizumab in Ovarian Cancer ⬇️

artículo científico publicado el 29 de diciembre de 2011

A phase I study of the trinuclear platinum compound, BBR 3464, in combination with protracted venous infusional 5-fluorouracil in patients with advanced cancer.

artículo científico publicado en 2003

A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocol

artículo científico publicado en 2014

An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib.

artículo científico publicado en 2016

Anterior Gradient-3: A novel biomarker for ovarian cancer that mediates cisplatin resistance in xenograft models ⬇️

artículo científico publicado el 15 de febrero de 2012

Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer

artículo científico publicado en 2012

BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer

artículo científico publicado en 2011

Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer

artículo científico publicado en 2017

Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial

artículo científico publicado en 2015

Cisplatin and Doxorubicin Induce Distinct Mechanisms of Ovarian Follicle Loss; Imatinib Provides Selective Protection Only against Cisplatin ⬇️

artículo científico publicado el 29 de julio de 2013

Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer

artículo científico publicado en 2017

Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study

artículo científico

Endocrine therapy in epithelial ovarian cancer

artículo científico publicado en 2016

Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations.

artículo científico publicado en 2018

Erratum to Genetic and molecular changes in ovarian cancer

artículo científico publicado en 2017

Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OC

artículo científico publicado en 2017

First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5): a feasibility study and comparative analysis of the SCOTROC series

artículo científico publicado en 2010

Genetic and molecular changes in ovarian cancer

artículo científico publicado en 2016

Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer

artículo científico publicado en 2014

Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian and primary peritoneal low-grade serous carcinomas.

artículo científico publicado en 2014

Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions

scientific article published on 26 February 2019

HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer.

artículo científico publicado en 2011

Hormone receptors and ovarian cancer survival ⬇️

artículo científico publicado el 9 de julio de 2013

ICON 9-an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemo

artículo científico publicado en 2020

Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancer

artículo científico publicado en 2012

Integrated collaborative care for comorbid major depression in patients with cancer (SMaRT Oncology-2): a multicentre randomised controlled effectiveness trial

artículo científico publicado en 2014

Integrated collaborative care for major depression comorbid with a poor prognosis cancer (SMaRT Oncology-3): a multicentre randomised controlled trial in patients with lung cancer

artículo científico publicado en 2014

Interventions for the treatment of borderline ovarian tumours

artículo científico publicado en 2010

Interventions for the treatment of borderline ovarian tumours

artículo científico publicado en 2009

Low-grade epithelial ovarian cancer: a number of distinct clinical entities?

artículo científico

Melanoma cells replicate through chemotherapy by reducing levels of key homologous recombination protein RAD51 and increasing expression of translesion synthesis DNA polymerase ζ.

artículo científico publicado en 2017

Mismatch repair deficiency in ovarian cancer -- molecular characteristics and clinical implications

artículo científico

Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome

artículo científico publicado en 2020

OV21/PETROC: A randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer

artículo científico publicado en 2017

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.

artículo científico publicado en 2014

Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy.

artículo científico

Ovarian Cancer Molecular Stratification and Tumor Heterogeneity: A Necessity and a Challenge

artículo científico publicado en 2015

Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.

artículo científico

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval

artículo científico publicado en 2010

Prediction of anti-angiogenesis escape

artículo científico publicado en 2015

Prior knowledge transfer across transcriptional data sets and technologies using compositional statistics yields new mislabelled ovarian cell line

artículo científico publicado en 2016

Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer.

artículo científico publicado en 2016

Rab25 and CLIC3 collaborate to promote integrin recycling from late endosomes/lysosomes and drive cancer progression.

artículo científico publicado en 2011

Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses

artículo científico publicado en 2020

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer

artículo científico publicado en 2015

Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma-experience of the BriTROC consortium.

artículo científico publicado en 2017

Structural Variants at the <i>BRCA1/2</i> Loci are a Common Source of Homologous Repair Deficiency in High-grade Serous Ovarian Carcinoma

artículo científico publicado en 2021

Targeted anti-vascular therapies for ovarian cancer: current evidence ⬇️

artículo científico publicado en 2013

The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin

artículo científico publicado en 2016

The molecular origin and taxonomy of mucinous ovarian carcinoma

scientific article published on 02 September 2019

The safety and efficacy of olaparib therapy in patients with relapsed ovarian cancer

artículo científico publicado en 2016

The use of cisplatin to treat advanced-stage cervical cancer during pregnancy allows fetal development and prevents cancer progression: report of a case and review of the literature

artículo científico publicado en 2009

Update on Intraperitoneal Chemotherapy for the Treatment of Epithelial Ovarian Cancer

artículo científico publicado en 2016

Using serum CA125 to assess the activity of potential cytostatic agents in ovarian cancer

artículo científico publicado en 2014

WWOX gene expression abolishes ovarian cancer tumorigenicity in vivo and decreases attachment to fibronectin via integrin alpha3.

artículo científico publicado en 2009

WWOX tumour suppressor gene polymorphisms and ovarian cancer pathology and prognosis.

artículo científico publicado en 2010

Lista de obras de

A Phase 3 Trial of Bevacizumab in Ovarian Cancer ⬇️

A phase I study of the trinuclear platinum compound, BBR 3464, in combination with protracted venous infusional 5-fluorouracil in patients with advanced cancer.

A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocol

An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib.

Anterior Gradient-3: A novel biomarker for ovarian cancer that mediates cisplatin resistance in xenograft models ⬇️

Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer

BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer

Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer

Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial

Cisplatin and Doxorubicin Induce Distinct Mechanisms of Ovarian Follicle Loss; Imatinib Provides Selective Protection Only against Cisplatin ⬇️

Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer

Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study

Endocrine therapy in epithelial ovarian cancer

Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations.

Erratum to Genetic and molecular changes in ovarian cancer

Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OC

First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5): a feasibility study and comparative analysis of the SCOTROC series

Genetic and molecular changes in ovarian cancer

Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer

Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian and primary peritoneal low-grade serous carcinomas.

Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions

HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer.

Hormone receptors and ovarian cancer survival ⬇️

ICON 9-an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemo

Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancer

Integrated collaborative care for comorbid major depression in patients with cancer (SMaRT Oncology-2): a multicentre randomised controlled effectiveness trial

Integrated collaborative care for major depression comorbid with a poor prognosis cancer (SMaRT Oncology-3): a multicentre randomised controlled trial in patients with lung cancer

Interventions for the treatment of borderline ovarian tumours

Interventions for the treatment of borderline ovarian tumours

Low-grade epithelial ovarian cancer: a number of distinct clinical entities?

Melanoma cells replicate through chemotherapy by reducing levels of key homologous recombination protein RAD51 and increasing expression of translesion synthesis DNA polymerase ζ.

Mismatch repair deficiency in ovarian cancer -- molecular characteristics and clinical implications

Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome

OV21/PETROC: A randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.

Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy.

Ovarian Cancer Molecular Stratification and Tumor Heterogeneity: A Necessity and a Challenge

Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval

Prediction of anti-angiogenesis escape

Prior knowledge transfer across transcriptional data sets and technologies using compositional statistics yields new mislabelled ovarian cell line

Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer.

Rab25 and CLIC3 collaborate to promote integrin recycling from late endosomes/lysosomes and drive cancer progression.

Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer

Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma-experience of the BriTROC consortium.

Structural Variants at the <i>BRCA1/2</i> Loci are a Common Source of Homologous Repair Deficiency in High-grade Serous Ovarian Carcinoma

Targeted anti-vascular therapies for ovarian cancer: current evidence ⬇️

The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin

The molecular origin and taxonomy of mucinous ovarian carcinoma

The safety and efficacy of olaparib therapy in patients with relapsed ovarian cancer

The use of cisplatin to treat advanced-stage cervical cancer during pregnancy allows fetal development and prevents cancer progression: report of a case and review of the literature

Update on Intraperitoneal Chemotherapy for the Treatment of Epithelial Ovarian Cancer

Using serum CA125 to assess the activity of potential cytostatic agents in ovarian cancer

WWOX gene expression abolishes ovarian cancer tumorigenicity in vivo and decreases attachment to fibronectin via integrin alpha3.

WWOX tumour suppressor gene polymorphisms and ovarian cancer pathology and prognosis.